Abstract
Severe asthma is a high-cost chronic disease with different inflammatory phenotypes, the eosinophilic phenotype being the most common. Benralizumab is a monoclonal antibody that targets this phenotype. This study evaluated cost-utility ratio of Benralizumab in patients with severe eosinophilic asthma in Costa Rica.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.